Inflammation biomarkers in OSA, chronic obstructive pulmonary disease, and chronic obstructive pulmonary disease/OSA overlap syndrome.

Autor:	Sanchez-Azofra A; Division of Pulmonary, Critical Care, and Sleep Medicine and Physiology, Department of Medicine, University of California, La Jolla, California.; Division of Pulmonary and Sleep Medicine. Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Madrid, España., Gu W; Division of Pulmonary, Critical Care, and Sleep Medicine and Physiology, Department of Medicine, University of California, La Jolla, California.; Herbert Wertheim School of Public Health and Longevity Sciences, University of California, San Diego, La Jolla, California., Masso-Silva JA; Division of Pulmonary, Critical Care, and Sleep Medicine and Physiology, Department of Medicine, University of California, La Jolla, California.; Section of Pulmonary and Critical Care, VA San Diego, La Jolla, California., Sanz-Rubio D; Translational Research Unit, IIS Aragón, Hospital Universitario Miguel Servet, Zaragoza, Spain., Marin-Oto M; Translational Research Unit, IIS Aragón, Hospital Universitario Miguel Servet, Zaragoza, Spain., Cubero P; Translational Research Unit, IIS Aragón, Hospital Universitario Miguel Servet, Zaragoza, Spain., Gil AV; Translational Research Unit, IIS Aragón, Hospital Universitario Miguel Servet, Zaragoza, Spain., Moya EA; Division of Pulmonary, Critical Care, and Sleep Medicine and Physiology, Department of Medicine, University of California, La Jolla, California., Barnes LA; Division of Pulmonary, Critical Care, and Sleep Medicine and Physiology, Department of Medicine, University of California, La Jolla, California., Mesarwi OA; Division of Pulmonary, Critical Care, and Sleep Medicine and Physiology, Department of Medicine, University of California, La Jolla, California., Marin T; Division of Pulmonary, Critical Care, and Sleep Medicine and Physiology, Department of Medicine, University of California, La Jolla, California.; Health Sciences, Department of Respiratory Therapy, Victor Valley College, Victorville, California., Simonson TS; Division of Pulmonary, Critical Care, and Sleep Medicine and Physiology, Department of Medicine, University of California, La Jolla, California.; Center for Physiological Genomics of Low Oxygen, University of California, La Jolla, California., Crotty Alexander LE; Division of Pulmonary, Critical Care, and Sleep Medicine and Physiology, Department of Medicine, University of California, La Jolla, California.; Section of Pulmonary and Critical Care, VA San Diego, La Jolla, California., Marin JM; Translational Research Unit, IIS Aragón, Hospital Universitario Miguel Servet, Zaragoza, Spain.; CIBERES Instituto Salud Carlos III, and Department of Medicine, University of Zaragoza School of Medicine, Zaragoza, Spain., Malhotra A; Division of Pulmonary, Critical Care, and Sleep Medicine and Physiology, Department of Medicine, University of California, La Jolla, California.; Center for Physiological Genomics of Low Oxygen, University of California, La Jolla, California.
Jazyk:	angličtina
Zdroj:	Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine [J Clin Sleep Med] 2023 Aug 01; Vol. 19 (8), pp. 1447-1456.
DOI:	10.5664/jcsm.10600
Abstrakt:	Study Objectives: The coexistence of obstructive sleep apnea (OSA) and chronic obstructive pulmonary disease (COPD) in a single individual, also known as overlap syndrome (OVS), is associated with higher cardiovascular risk and mortality than either OSA or COPD alone. However, the underlying mechanisms remain unclear. We hypothesized that patients with OVS have elevated systemic inflammatory biomarkers relative to patients with either disease alone, which could explain greater cardiovascular risk observed in OVS. Methods: We included 255 participants in the study, 55 with COPD alone, 100 with OSA alone, 50 with OVS, and 50 healthy controls. All participants underwent a home sleep study, spirometry, and a blood draw for high-sensitivity C-reactive protein and total blood count analysis. In a randomly selected subset of 186 participants, inflammatory protein profiling was performed using Bio-Rad Bio-Plex Pro Human Cytokine 27-Plex Assays. Biomarker level differences across groups were identified using a mixed linear model. Results: Levels of interleukin 6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), and granulocyte colony stimulating factor (G-CSF) were higher in participants with OVS and COPD compared with healthy controls and participants with OSA. Furthermore, participants with OVS had higher circulating levels of leukocytes and neutrophils than those with COPD, OSA, and controls. Conclusions: COPD and OVS are associated with higher systemic inflammation relative to OSA and healthy controls. This work proposes the potential utilization of interleukin 6, granulocyte colony stimulating factor, and high-sensitivity C-reactive protein as screening biomarkers for COPD in patients with OSA. Inflammatory pathways may not fully explain the higher cardiovascular risk observed in OVS, indicating the need for further investigation. Citation: Sanchez-Azofra A, Gu W, Masso-Silva JA, et al. Inflammation biomarkers in OSA, chronic obstructive pulmonary disease, and chronic obstructive pulmonary disease/OSA overlap syndrome. J Clin Sleep Med . 2023;19(8):1447-1456. (© 2023 American Academy of Sleep Medicine.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu